A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement
A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement therapies such as Premarin from American Home Products.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.